150 related articles for article (PubMed ID: 35025993)
1. Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk.
Tardif JC; Karwatowska-Prokopczuk E; Amour ES; Ballantyne CM; Shapiro MD; Moriarty PM; Baum SJ; Hurh E; Bartlett VJ; Kingsbury J; Figueroa AL; Alexander VJ; Tami J; Witztum JL; Geary RS; O'Dea LSL; Tsimikas S; Gaudet D
Eur Heart J; 2022 Apr; 43(14):1401-1412. PubMed ID: 35025993
[TBL] [Abstract][Full Text] [Related]
2. Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk.
Bergmark BA; Marston NA; Prohaska TA; Alexander VJ; Zimerman A; Moura FA; Murphy SA; Goodrich EL; Zhang S; Gaudet D; Karwatowska-Prokopczuk E; Tsimikas S; Giugliano RP; Sabatine MS;
N Engl J Med; 2024 May; 390(19):1770-1780. PubMed ID: 38587249
[TBL] [Abstract][Full Text] [Related]
3. Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome.
Stroes ESG; Alexander VJ; Karwatowska-Prokopczuk E; Hegele RA; Arca M; Ballantyne CM; Soran H; Prohaska TA; Xia S; Ginsberg HN; Witztum JL; Tsimikas S;
N Engl J Med; 2024 May; 390(19):1781-1792. PubMed ID: 38587247
[TBL] [Abstract][Full Text] [Related]
4. Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia: The SHASTA-2 Randomized Clinical Trial.
Gaudet D; Pall D; Watts GF; Nicholls SJ; Rosenson RS; Modesto K; San Martin J; Hellawell J; Ballantyne CM
JAMA Cardiol; 2024 Apr; ():. PubMed ID: 38583092
[TBL] [Abstract][Full Text] [Related]
5. APOC3 inhibition with volanesorsen reduces hepatic steatosis in patients with severe hypertriglyceridemia.
Prohaska TA; Alexander VJ; Karwatowska-Prokopczuk E; Tami J; Xia S; Witztum JL; Tsimikas S
J Clin Lipidol; 2023; 17(3):406-411. PubMed ID: 37164837
[TBL] [Abstract][Full Text] [Related]
6. Volanesorsen, an antisense oligonucleotide to apolipoprotein C-III, increases lipoprotein lipase activity and lowers triglycerides in partial lipodystrophy.
Lightbourne M; Startzell M; Bruce KD; Brite B; Muniyappa R; Skarulis M; Shamburek R; Gharib AM; Ouwerkerk R; Walter M; Eckel RH; Brown RJ
J Clin Lipidol; 2022; 16(6):850-862. PubMed ID: 36195542
[TBL] [Abstract][Full Text] [Related]
7. The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes.
Wilson JM; Nikooienejad A; Robins DA; Roell WC; Riesmeyer JS; Haupt A; Duffin KL; Taskinen MR; Ruotolo G
Diabetes Obes Metab; 2020 Dec; 22(12):2451-2459. PubMed ID: 33462955
[TBL] [Abstract][Full Text] [Related]
8. Interventional hepatic apoC-III knockdown improves atherosclerotic plaque stability and remodeling by triglyceride lowering.
Ramms B; Patel S; Sun X; Pessentheiner AR; Ducasa GM; Mullick AE; Lee RG; Crooke RM; Tsimikas S; Witztum JL; Gordts PL
JCI Insight; 2022 Jul; 7(13):. PubMed ID: 35653195
[TBL] [Abstract][Full Text] [Related]
9. RNA Interference Therapy Targeting Apolipoprotein C-III in Hypertriglyceridemia.
Gaudet D; Clifton P; Sullivan D; Baker J; Schwabe C; Thackwray S; Scott R; Hamilton J; Given B; Melquist S; Zhou R; Chang T; San Martin J; Watts GF; Goldberg IJ; Knowles JW; Hegele RA; Ballantyne CM
NEJM Evid; 2023 Dec; 2(12):EVIDoa2200325. PubMed ID: 38320498
[TBL] [Abstract][Full Text] [Related]
10. APOC3 siRNA and ASO therapy for dyslipidemia.
Chebli J; Larouche M; Gaudet D
Curr Opin Endocrinol Diabetes Obes; 2024 Apr; 31(2):70-77. PubMed ID: 38334488
[TBL] [Abstract][Full Text] [Related]
11. Apolipoprotein C-III, familial chylomicronemia syndrome, and olezarsen.
Valdivielso P; Coca Prieto I
Med; 2024 Jun; 5(6):493-494. PubMed ID: 38878767
[TBL] [Abstract][Full Text] [Related]
12. Exploring apolipoprotein C-III: pathophysiological and pharmacological relevance.
Packard CJ; Pirillo A; Tsimikas S; Ference BA; Catapano AL
Cardiovasc Res; 2024 Feb; 119(18):2843-2857. PubMed ID: 38039351
[TBL] [Abstract][Full Text] [Related]
13. Advances in Dyslipidaemia Treatments: Focusing on ApoC3 and ANGPTL3 Inhibitors.
Tomlinson B; Wu QY; Zhong YM; Li YH
J Lipid Atheroscler; 2024 Jan; 13(1):2-20. PubMed ID: 38299167
[TBL] [Abstract][Full Text] [Related]
14. Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia.
Ballantyne CM; Vasas S; Azizad M; Clifton P; Rosenson RS; Chang T; Melquist S; Zhou R; Mushin M; Leeper NJ; Hellawell J; Gaudet D
N Engl J Med; 2024 May; ():. PubMed ID: 38804517
[TBL] [Abstract][Full Text] [Related]
15. The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial.
Bhatt DL; Bays HE; Miller M; Cain JE; Wasilewska K; Andrawis NS; Parli T; Feng S; Sterling L; Tseng L; Hartsfield CL; Agollah GD; Mansbach H; Kastelein JJP;
Nat Med; 2023 Jul; 29(7):1782-1792. PubMed ID: 37355760
[TBL] [Abstract][Full Text] [Related]
16. Updates in Drug Treatment of Severe Hypertriglyceridemia.
Gouni-Berthold I; Schwarz J; Berthold HK
Curr Atheroscler Rep; 2023 Oct; 25(10):701-709. PubMed ID: 37642858
[TBL] [Abstract][Full Text] [Related]
17. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: Long-term efficacy and safety data from patients in an open-label extension trial.
Witztum JL; Gaudet D; Arca M; Jones A; Soran H; Gouni-Berthold I; Stroes ESG; Alexander VJ; Jones R; Watts L; Xia S; Tsimikas S
J Clin Lipidol; 2023; 17(3):342-355. PubMed ID: 37100699
[TBL] [Abstract][Full Text] [Related]
18. RNA-based therapies targeting APOC3 lower triglyceride levels in patients with hypertriglyceridaemia.
Huynh K
Nat Rev Cardiol; 2024 Jun; 21(6):353. PubMed ID: 38654089
[No Abstract] [Full Text] [Related]
19. Apolipoprotein C-III Inhibition - Killing Two Birds with One Stone?
Kraaijenhof JM; Stroes ESG
NEJM Evid; 2023 Dec; 2(12):EVIDe2300239. PubMed ID: 38320505
[TBL] [Abstract][Full Text] [Related]
20. Hypertriglyceridaemia: contemporary management of a neglected cardiovascular risk factor.
Khan TZ; Schatz U; Bornstein SR; Barbir M
Glob Cardiol Sci Pract; 2021 Oct; 2021(3):e202119. PubMed ID: 34805377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
